Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies

NO_LONGER_AVAILABLE

Conditions studied: Dravet Syndrome, Epileptic Encephalopathies Associated With SCN1A Mutations

In brief

This is an expanded access use of Stiripentol in Dravet Syndrome or epileptic encephalopathies associated with sodium channel mutations who have failed other drugs in an effort to give them the best chance at seizure control and quality of life. As a treatment protocol and not a research study, children will only be monitored on a clinical basis for seizure improvement and side effects predominantly by parent and caregiver report.

Key facts

Study ID

NCT02239276

Run by

Cook Children's Health Care System

Last updated by the study team

2020-02-05

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 6 months and older
• Diagnosis of Dravet Syndrome or epileptic encephalopathies associated with SCN1A mutations defined as:
• A documented gene mutation reported to result in Dravet syndrome phenotype; OR
• Clinical confirmation of Dravet syndrome by two pediatric neurologists; OR
• Clinical confirmation of other epileptic encephalopathies associated with sodium channel mutations
• Failure of at least 2 therapeutic anticonvulsants (excluding Na Channel blockers) indicative of intractable seizures

You may not qualify if…

• Hypersensitivity to the active substance or to any of the excipients
• Past history of psychoses in the form of episodes of delirium
• Impaired hepatic and/or renal function, defined as creatinine >2 and/or transaminase >4xULN

Where it is running

• Cook Children's Medical Center — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.